Modern methods of thrombosis prevention and treatment in cancer patients with atrial fibrillation: focus on apixaban

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Recent studies confirm that endothelial dysfunction is an important pathogenetic mechanism in both atrial fibrillation and cancer-associated thromboses. It promotes inflammation, activation of coagulation and development of thrombosis, which requires the development of new therapeutic approaches to reduce the risk of thromboembolic complications (TEC) in such patients. The ongoing trials support the use of apixaban for the treatment of venous TEC in patients with active oncopathology in combination with atrial fibrillation, which confirms its efficacy and safety. This allows apixaban to be used both in outpatient settings and for long-term treatment with minimal risks of major bleeding, which is an important step in improving the quality of life of cancer patients.

Full Text

Restricted Access

About the authors

O. A. Rubanenko

Samara State Medical University

Email: i.a.zolotovskaya@samsmu.ru
ORCID iD: 0000-0001-9351-6177
ResearcherId: I-8490-2015
Russian Federation, Samara

Irina A. Zolotovskaya

Samara State Medical University

Author for correspondence.
Email: i.a.zolotovskaya@samsmu.ru
ORCID iD: 0000-0002-0555-4016

Dr. Sci. (Med.), Professor, Department of Hospital Therapy with Courses in Hematology and Transfusiology

Russian Federation, Samara

P. R. Shatskaya

Samara State Medical University

Email: i.a.zolotovskaya@samsmu.ru
ORCID iD: 0000-0001-5183-1208
Russian Federation, Samara

References

  1. Fan B.E., Sum C.L.L., Leung B.P.L., et al. VEXAS Syndrome and Thrombosis: Findings of Inflammation, Hypercoagulability, and Endothelial Dysfunction. Semin Thromb Hemost. 2024;50(6):897–901. doi: 10.1055/s-0043-1778105.
  2. Poredos P., Jezovnik M.K. Endothelial Dysfunction and Venous Thrombosis. Angiology. 2018;69(7):564–67. doi: 10.1177/0003319717732238.
  3. Desantis V., Potenza M.A., Sgarra L., et al. MicroRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation. Int J Mol Sci. 2023;24(6):5307. doi: 10.3390/ijms24065307.
  4. Corban M.T., Toya T., Ahmad A., et al. Atrial Fibrillation and Endothelial Dysfunction: A Potential Link? Mayo Clin Proc. 2021;96(6):1609–21. doi: 10.1016/j.mayocp.2020.11.005.
  5. Black N., Mohammad F., Saraf K., Morris G. Endothelial function and atrial fibrillation: A missing piece of the puzzle? J Cardiovasc Electrophysiol. 2022;33(1):109–16. doi: 10.1111/jce.15277.
  6. Heshmat-Ghahdarijani K., Jangjoo S., Amirpour A., et al. Endothelial dysfunction in patients with lone atrial fibrillation. ARYA. Atheroscler. 2020;16(6):278–83. doi: 10.22122/arya.v16i6.2095.
  7. Mukai M., Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018;72(2):89–93. doi: 10.1016/j.jjcc.2018.02.011.
  8. Pavlovic D., Niciforovic D., Markovic M., Papic D. Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment. Clin Med Insights Oncol. 2023;17:11795549231220297. doi: 10.1177/11795549231220297.
  9. Pastori D., Gazzaniga G., Farcomeni A., et al. Venous Thromboembolism in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis of 4,170,027 Patients. JACC Adv. 2023;2(7):100555. doi: 10.1016/j.jacadv.2023.100555.
  10. Hamza M.S., Mousa S.A. Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. Clin Appl Thromb Hemost. 2020;26:1076029620954282. doi: 10.1177/1076029620954282.
  11. Chu G., Versteeg H.H., Verschoor A.J., et al. Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. Blood Rev. 2019;35:59–67. doi: 10.1016/j.blre.2019.03.005.
  12. Madnick D.L., Fradley M.G. Atrial Fibrillation and Cancer Patients: Mechanisms and Management. Curr. Cardiol Rep. 2022;24(10):1517–27. doi: 10.1007/s11886-022-01769-3.
  13. Penela D., Berruezo A., Cappato R. What do we really know about anticoagulation in patients with cancer and atrial fibrillation? Eur J Prev Cardiol. 2021;28(6):606–7. doi: 10.1093/eurjpc/zwaa106.
  14. Crea F. Cardio-oncology: a focus on cardiovascular toxicities of cancer therapies and on atrial fibrillation in cancer. Eur Heart J. 2022;43(4):245–48. doi: 10.1093/eurheartj/ehab905.
  15. Головина В.И., Селиверстов Е.И., Ан Е.С., Золотухин И.А. Антикоагулянтная терапия онкоассоциированных тромбозов глубоких вен: уроки рандомизированных исследований и реальной клинической практики. Флебология. 2022;16(2):156–63. [Golovina V.I., Seliverstov E.I., An E.S., Zolotukhin I.A. Cancer-Associated Deep Vein Thrombosis: Insights from Randomized Trials and Real-Life Practice. J Venous Disorders. 2022;16(2):156–63. (In Russ.)]. doi: 10.17116/ flebo202216021156.
  16. Potere N., Di Nisio M., Porreca E., et al. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial. Thromb Res. 2023;226:82–5. doi: 10.1016/j.thromres.2023.04.015.
  17. McBane R.D., Wysokinski W.E., Le-Rademacher J.G., et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J. Thromb. Haemost. 2020;18(2):411–21. doi: 10.1111/ jth.14662.
  18. Agnelli G., Becattini C., Meyer G., et al. Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N. Engl. J. Med. 2020;382(17):1599–607. doi: 10.1056/NEJMoa1915103.
  19. Lopez Robles J., Carmona-Bayonas A., Jimenez-Fonseca P. Decoding risk: Caravaggio’s insights into risk factors for anticoagulation in cancer-associated thrombosis. Eur J Intern Med. 2023;112:21–3. doi: 10.1016/j.ejim.2023.03.022.
  20. Ording A.G., Sogaard M., Skjoth F., et al. Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. Cancer Med. 2021;10(13):4405–14. doi: 10.1002/cam4.4012.
  21. Панченко Е.П. Роль апиксабана в лечении венозных тромбоэмболических осложнений у больных с активным раком. Атеротромбоз. 2020;(1):47–54. [Panchenko E.P. Role of apixaban in the treatment of venous thromboembolic complications in patients with active cancer. Atherothrombosis. 2020;(1):47–54. (In Russ.)]. doi: 10.21518/2307-1109-2020-1-3-54.
  22. Dhami S.P.S., Patmore S., O’Sullivan J.M. Advances in the Management of Cancer-Associated Thrombosis. Semin Thromb Hemost. 2021;47(2):139–49. doi: 10.1055/s-0041-1722863.
  23. Deng Y., Tong Y., Deng Y., et al. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019;8(14):e012540. doi: 10.1161/JAHA.119.012540.
  24. Dirienzo L., Vitulli A., Mancazzo F., et al. Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism. Blood Transfus. 2022;20(6):505–15. doi: 10.2450/2021.0153-21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bionika Media